Brucella

Jump to navigation Jump to search
Brucella

Scientific classification
Kingdom: Bacteria
Phylum: Proteobacteria
Class: Alpha Proteobacteria
Order: Rhizobiales
Family: Brucellaceae
Genus: Brucella
Species

B. abortus
B. canis
B. melitensis
B. neotomae
B. ovis
B. suis

WikiDoc Resources for Brucella

Articles

Most recent articles on Brucella

Most cited articles on Brucella

Review articles on Brucella

Articles on Brucella in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Brucella

Images of Brucella

Photos of Brucella

Podcasts & MP3s on Brucella

Videos on Brucella

Evidence Based Medicine

Cochrane Collaboration on Brucella

Bandolier on Brucella

TRIP on Brucella

Clinical Trials

Ongoing Trials on Brucella at Clinical Trials.gov

Trial results on Brucella

Clinical Trials on Brucella at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Brucella

NICE Guidance on Brucella

NHS PRODIGY Guidance

FDA on Brucella

CDC on Brucella

Books

Books on Brucella

News

Brucella in the news

Be alerted to news on Brucella

News trends on Brucella

Commentary

Blogs on Brucella

Definitions

Definitions of Brucella

Patient Resources / Community

Patient resources on Brucella

Discussion groups on Brucella

Patient Handouts on Brucella

Directions to Hospitals Treating Brucella

Risk calculators and risk factors for Brucella

Healthcare Provider Resources

Symptoms of Brucella

Causes & Risk Factors for Brucella

Diagnostic studies for Brucella

Treatment of Brucella

Continuing Medical Education (CME)

CME Programs on Brucella

International

Brucella en Espanol

Brucella en Francais

Business

Brucella in the Marketplace

Patents on Brucella

Experimental / Informatics

List of terms related to Brucella

Overview

Brucella is a genus of Gram-negative bacteria.[1] They are small (0.5 to 0.7 by 0.6 to 1.5 µm), non-motile, encapsulated coccobacilli.

Brucella is the cause of brucellosis, a true zoonotic disease (i.e. human-to-human transmission has not been identified).[1] It is transmitted by ingesting infected food, direct contact with an infected animal, or inhalation of aerosols. Minimum infectious exposure is between 10 - 100 organisms. Brucellosis primarily occurs through occupational exposure (e.g. exposure to cattle, sheep, pigs), but also by consumption of unpasteurised milk products.

There are a few different species of Brucella, each with a slightly different presentation, such as B. melitensis, B. abortus, B. suis and B. citicosis.

Laboratory isolation

Brucella are slow-growing, but may be isolated from normal blood cultures using standard media. In traditional blood culture media, prolonged incubation (up to 6 weeks) may be required, but on modern automated machines the cultures often come positive within seven days. On Gram stain they appear as dense clumps of Gram-negative coccobacilli and are exceedingly difficult to see.

Laboratory acquired brucellosis is common.[2] This most often happens when the disease is not thought of until cultures become positive, by which time the specimens have already been handled by a number of laboratory staff. The idea of preventative treatment is to stop people who have been exposed to Brucella from becoming unwell with the disease.

There are no clinical trials to be relied on as a guide for optimal treatment, but a three week course of rifampicin and doxycycline twice daily is the combination most often used, and appears to be efficacious;[2][3] the advantage of this regimen is that it can be taken by mouth and there are no injections, however, a high rate of side effects (nausea, vomiting, loss of appetite) has also been reported.[3]

Blue light study

In a study published in Science magazine in August of 2007, it was revealed that Brucella reacts strongly to the presence of the blue spectrum in natural light, reproducing at a great rate and becoming infectious. Conversely, depriving Brucella of the blue wavelengths dropped its reproductive rate by 90%, a result one of the co-authors called "spectacular."[4][5]

Treatment

  • Uncomplicated brucellosis in adults and children eight years of age and older [6]
  • Preferred regimen: Doxycycline 100 mg PO bid for 6 weeks OR Tetracycline 500 mg every six hours orally administered for at least six weeks
  • NOTE: Streptomycin 1 g/day intramuscularly administered for the first two to three weeks of therapy OR Gentamicin 5mg/kg/day intravenously or intramuscularly for 7-10 days in combination with Doxycycline administered for six weeks
  • Alternative regimen (1): Doxycycline 200 mg/day orally AND Rifampicin 600–900 mg/day orally, both drugs administered for six weeks
  • Alternative regimen (2): Fluoroquinolones
  • NTOE: Quinolones should always be used in combination with other drugs, such as Doxycycline or Rifampicin
  • Alternative regimen (3): TMP/SMZ in a fixed ratio of 1:5 (80 mg TMP/400 mg SMZ)
  • NOTE: TMP/SMZ should always be used in combination with another agent, such as Doxycycline, Rifampicin or Streptomycin
  • Complications of brucellosis
  • Spondylitis
  • Preferred regimen: Continuation of Doxycycline for eight weeks or more; Surgical drainage is rarely necessary.
  • Neurobrucellosis
  • Brucella endocarditis
  • For children less than eight years of age
  • Preferred regimen: TMP/SMZ 8/40 mg/ kg/day bid orally administered for six weeks AND Streptomycin 30 mg/kg/day once daily intramuscularly administered for three weeks OR Gentamicin 5 mg/kg/day once daily intravenously or intramuscularly administered for 7-10 days
  • Alternative regimen (1): TMP/SMZ AND Rifampicin 15 mg/kg/day orally each administered for 6 weeks

References

  1. 1.0 1.1 Ryan KJ, Ray CG (editors) (2004). Sherris Medical Microbiology (4th ed. ed.). McGraw Hill. ISBN 0-8385-8529-9.
  2. 2.0 2.1 Robichaud S, Libman M, Behr M, Rubin E (2004). "Prevention of laboratory-acquired brucellosis". Clin. Infect. Dis. 38 (12): e119–22. doi:10.1086/421024. PMID 15227634.
  3. 3.0 3.1 Maley MW, Kociuba K, Chan RC (2006). "Prevention of laboratory-acquired brucellosis: significant side effects of prophylaxis". Clin. Infect. Dis. 42 (3): 433–4. doi:10.1086/499112. PMID 16392095.
  4. "Deadly in the Daylight" August 23, 2007 in ScienceNOW Daily News. Accessed September 8, 2007.
  5. [http://www.sciencemag.org/cgi/content/abstract/317/5841/1090 "Blue-Light-Activated Histidine Kinases: Two-Component Sensors in Bacteria "], August 24 2007, Science Vol. 317:5841, pp. 1090 - 1093 Accessed September 8, 2007.
  6. Corbel, Michael (2006). Brucellosis in humans and animals. Geneva: World Health Organization. ISBN 9241547138.

External links


de:Brucellen fa:بروسلا it:Brucella he:Brucella uk:Бруцела

Template:WS